Abstract
Mental illness is often characterised by a maladaptive sense of self. The neurobiological basis of Self-Other distinction may provide targets for therapeutic interventions. Psychedelics alter the experience of selfhood, but the neurocomputational mechanism is unclear. We used a computationally-informed behavioural assay to investigate whether psychedelics disrupt Self-Other boundaries in belief formation. In a double-blind, crossover design, 22 participants received placebo, psilocybin or 2C-B (2,5-dimethoxy-4-bromophenethylamine). The next day, we fitted reinforcement learning models to probabilistic false-belief task behaviour, yielding objective Self-Other distinction measures. Compared to placebo, psychedelics induced a state of Self-Other mergence, associated with a multivariate signal of sustained psychosocial wellbeing. Effective-connectivity estimates from resting-state fMRI showed that Self-Other boundary disruption was associated with reduced inhibitory tone from right temporoparietal junction to dorsomedial prefrontal cortex. We show that psychedelics quantifiably act on the neural basis of Self-Other distinction, offering potential routes to precision therapeutics in psychedelic psychiatry.
Competing Interest Statement
Johannes G. Ramaekers is a scientific consultant to GH Research who have no involvement in the preparation or conception of this manuscript or related data. K.P. is currently an employee of Boehringer Ingelheim GmbH & Co KG, and is currently Chief Scientist and on the Board of Directors for the Heffter Research Institute, and scientific advisor for the MIND foundation. All other authors have no relevant conflicts of interest to declare.
Clinical Trial
NL8813
Funding Statement
Johannes G. Ramaekers acknowledges financial support from the Dutch Research Council (NWO, grant number 406.18. GO.019). NLM is financially supported by the Dutch Research Council (NWO, grant number VI.Veni.231G.011).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data were collected as part of a larger trial (trial register: NL8813, approved by the Academic Hospital and the University's Medical Ethics Committee of Maastricht University (NL73539.068.20)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest: Johannes G. Ramaekers is a scientific consultant to GH Research who have no involvement in the preparation or conception of this manuscript or related data. K.P. is currently an employee of Boehringer Ingelheim GmbH & Co KG, and is currently Chief Scientist and on the Board of Directors for the Heffter Research Institute, and scientific advisor for the MIND foundation. All other authors have no relevant conflicts of interest to declare.
Funding Johannes G. Ramaekers acknowledges financial support from the Dutch Research Council (NWO, grant number 406.18. GO.019). NLM is financially supported by the Dutch Research Council (NWO, grant number VI.Veni.231G.011).
